(Q35058694)

6 August 2017

title

Management of chronic myeloid leukemia: targets for molecular therapy (English)

1 reference

6 August 2017

main subject

chronic myeloid leukemia

0 references

author name string

David J Barnes

series ordinal

1

1 reference

6 August 2017

Junia V Melo

series ordinal

2

1 reference

6 August 2017

publication date

1 January 2003

1 reference

6 August 2017

published in

Seminars in Hematology

1 reference

6 August 2017

volume

40

1 reference

6 August 2017

issue

1

1 reference

6 August 2017

page(s)

34-49

1 reference

Roots of clinical resistance to STI-571 cancer therapy

6 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016/S0037-1963(03)70041-9

7 January 2021

Disabling receptor ensembles with rationally designed interface peptidomimetics

1 reference

https://api.crossref.org/works/10.1016/S0037-1963(03)70041-9

7 January 2021

Hsp-90-associated oncoproteins: multiple targets of geldanamycin and its analogs

1 reference

https://api.crossref.org/works/10.1016/S0037-1963(03)70041-9

7 January 2021

STI-571 must select for drug-resistant cells but 'no cell breathes fire out of its nostrils like a dragon'.

1 reference

https://api.crossref.org/works/10.1016/S0037-1963(03)70041-9

7 January 2021

Novel antisense and peptide nucleic acid strategies for controlling gene expression

1 reference

https://api.crossref.org/works/10.1016/S0037-1963(03)70041-9

7 January 2021

High frequency of point mutations clustered within the adenosine triphosphate-binding region of BCR/ABL in patients with chronic myeloid leukemia or Ph-positive acute lymphoblastic leukemia who develop imatinib (STI571) resistance

1 reference

https://api.crossref.org/works/10.1016/S0037-1963(03)70041-9

7 January 2021

Glivec (STI571, imatinib), a rationally developed, targeted anticancer drug

1 reference

https://api.crossref.org/works/10.1016/S0037-1963(03)70041-9

7 January 2021

Lessons learned from the development of an abl tyrosine kinase inhibitor for chronic myelogenous leukemia

1 reference

https://api.crossref.org/works/10.1016/S0037-1963(03)70041-9

7 January 2021

Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1016/S0037-1963(03)70041-9

7 January 2021

Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells

1 reference

https://api.crossref.org/works/10.1016/S0037-1963(03)70041-9

7 January 2021

Farnesyltransferase inhibitors: Ras research yields a potential cancer therapeutic

1 reference

https://api.crossref.org/works/10.1016/S0037-1963(03)70041-9

7 January 2021

BCR-ABL point mutants isolated from patients with imatinib mesylate-resistant chronic myeloid leukemia remain sensitive to inhibitors of the BCR-ABL chaperone heat shock protein 90.

1 reference

https://api.crossref.org/works/10.1016/S0037-1963(03)70041-9

7 January 2021

Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification

1 reference

https://api.crossref.org/works/10.1016/S0037-1963(03)70041-9

7 January 2021

Peptide containing the BCR oligomerization domain (AA 1-160) reverses the transformed phenotype of p210bcr-abl positive 32D myeloid leukemia cells

1 reference

https://api.crossref.org/works/10.1016/S0037-1963(03)70041-9

7 January 2021

The coiled-coil domain and Tyr177 of bcr are required to induce a murine chronic myelogenous leukemia-like disease by bcr/abl.

1 reference

https://api.crossref.org/works/10.1016/S0037-1963(03)70041-9

7 January 2021

Ph( ) acute lymphoblastic leukemia resistant to the tyrosine kinase inhibitor STI571 has a unique BCR-ABL gene mutation

1 reference

https://api.crossref.org/works/10.1016/S0037-1963(03)70041-9

7 January 2021

Overcoming STI571 resistance with the farnesyl transferase inhibitor SCH66336.

1 reference

https://api.crossref.org/works/10.1016/S0037-1963(03)70041-9

7 January 2021

P210 and P190(BCR/ABL) induce the tyrosine phosphorylation and DNA binding activity of multiple specific STAT family members

1 reference

https://api.crossref.org/works/10.1016/S0037-1963(03)70041-9

7 January 2021

The inhibition of ERK/MAPK not the activation of JNK/SAPK is primarily required to induce apoptosis in chronic myelogenous leukemic K562 cells

1 reference

https://api.crossref.org/works/10.1016/S0037-1963(03)70041-9

7 January 2021

In vitro cytotoxic effects of a tyrosine kinase inhibitor STI571 in combination with commonly used antileukemic agents

1 reference

https://api.crossref.org/works/10.1016/S0037-1963(03)70041-9

7 January 2021

Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia

1 reference

https://api.crossref.org/works/10.1016/S0037-1963(03)70041-9

7 January 2021

Chronic myelogenous leukemia blast cell proliferation is inhibited by peptides that disrupt Grb2-SoS complexes

1 reference

https://api.crossref.org/works/10.1016/S0037-1963(03)70041-9

7 January 2021

Cell-penetrating SH3 domain blocker peptides inhibit proliferation of primary blast cells from CML patients

1 reference

https://api.crossref.org/works/10.1016/S0037-1963(03)70041-9

7 January 2021

Clinical and biologic activity of the farnesyltransferase inhibitor R115777 in adults with refractory and relapsed acute leukemias: a phase 1 clinical-laboratory correlative trial

1 reference

https://api.crossref.org/works/10.1016/S0037-1963(03)70041-9

7 January 2021

Isoprenoid addition to Ras protein is the critical modification for its membrane association and transforming activity

1 reference

https://api.crossref.org/works/10.1016/S0037-1963(03)70041-9

7 January 2021

Phosphatidylinositol-3 kinase inhibitors enhance the anti-leukemia effect of STI571.

1 reference

https://api.crossref.org/works/10.1016/S0037-1963(03)70041-9

7 January 2021

In vitro studies of the combination of imatinib mesylate (Gleevec) and arsenic trioxide (Trisenox) in chronic myelogenous leukemia

1 reference

https://api.crossref.org/works/10.1016/S0037-1963(03)70041-9

7 January 2021

Prenylation of RhoB is required for its cell transforming function but not its ability to activate serum response element-dependent transcription

1 reference

https://api.crossref.org/works/10.1016/S0037-1963(03)70041-9

7 January 2021

Tyrosine kinase inhibition: an approach to drug development

1 reference

https://api.crossref.org/works/10.1016/S0037-1963(03)70041-9

7 January 2021

Oligodeoxynucleotide-mediated inhibition of c-myb gene expression in autografted bone marrow: a pilot study

1 reference

https://api.crossref.org/works/10.1016/S0037-1963(03)70041-9

7 January 2021

Tyrosine kinase activity and transformation potency of bcr-abl oncogene products.

1 reference

https://api.crossref.org/works/10.1016/S0037-1963(03)70041-9

7 January 2021

Acquired resistance to imatinib mesylate: selection for pre-existing mutant cells

1 reference

https://api.crossref.org/works/10.1016/S0037-1963(03)70041-9

7 January 2021

Ras recruits Raf-1 to the plasma membrane for activation by tyrosine phosphorylation

1 reference

https://api.crossref.org/works/10.1016/S0037-1963(03)70041-9

7 January 2021

Effects of combinations of therapeutic agents on the proliferation of progenitor cells in chronic myeloid leukaemia

1 reference

https://api.crossref.org/works/10.1016/S0037-1963(03)70041-9

7 January 2021

A coiled-coil oligomerization domain of Bcr is essential for the transforming function of Bcr-Abl oncoproteins

1 reference

https://api.crossref.org/works/10.1016/S0037-1963(03)70041-9

7 January 2021

Inviting leukemic cells to waltz with the devil

1 reference

https://api.crossref.org/works/10.1016/S0037-1963(03)70041-9

7 January 2021

Effects of the Bcr/abl kinase inhibitors STI571 and adaphostin (NSC 680410) on chronic myelogenous leukemia cells in vitro

1 reference

https://api.crossref.org/works/10.1016/S0037-1963(03)70041-9

7 January 2021

Multifaceted approach to the treatment of bcr-abl-positive leukemias.

1 reference

https://api.crossref.org/works/10.1016/S0037-1963(03)70041-9

7 January 2021

ARG tyrosine kinase activity is inhibited by STI571.

1 reference

https://api.crossref.org/works/10.1016/S0037-1963(03)70041-9

7 January 2021

Activity of the farnesyl protein transferase inhibitor SCH66336 against BCR/ABL-induced murine leukemia and primary cells from patients with chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1016/S0037-1963(03)70041-9

7 January 2021

Bcr-Abl oncoproteins bind directly to activators of the Ras signalling pathway

1 reference

https://api.crossref.org/works/10.1016/S0037-1963(03)70041-9

7 January 2021

Treatment of Bcr/Abl-positive acute lymphoblastic leukemia in P190 transgenic mice with the farnesyl transferase inhibitor SCH66336.

1 reference

https://api.crossref.org/works/10.1016/S0037-1963(03)70041-9

7 January 2021

Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study.

1 reference

https://api.crossref.org/works/10.1016/S0037-1963(03)70041-9

7 January 2021

Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1016/S0037-1963(03)70041-9

7 January 2021

Suppression of Philadelphia1 leukemia cell growth in mice by BCR-ABL antisense oligodeoxynucleotide

1 reference

https://api.crossref.org/works/10.1016/S0037-1963(03)70041-9

7 January 2021

Nuclear-cytoplasmic shuttling of C-ABL tyrosine kinase

1 reference

https://api.crossref.org/works/10.1016/S0037-1963(03)70041-9

7 January 2021

Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study

1 reference

https://api.crossref.org/works/10.1016/S0037-1963(03)70041-9

7 January 2021

Oncogene inactivation in a mouse model

1 reference

https://api.crossref.org/works/10.1016/S0037-1963(03)70041-9

7 January 2021

Synergistic activity of the new ABL-specific tyrosine kinase inhibitor STI571 and chemotherapeutic drugs on BCR-ABL-positive chronic myelogenous leukemia cells

1 reference

https://api.crossref.org/works/10.1016/S0037-1963(03)70041-9

7 January 2021

Phenotypic change from transformed to normal induced by benzoquinonoid ansamycins accompanies inactivation of p60src in rat kidney cells infected with Rous sarcoma virus

1 reference

https://api.crossref.org/works/10.1016/S0037-1963(03)70041-9

7 January 2021

Cycling, stressed-out and nervous: cellular functions of c-Abl

1 reference

https://api.crossref.org/works/10.1016/S0037-1963(03)70041-9

7 January 2021

Induction of apoptosis in chronic myelogenous leukemia cells through nuclear entrapment of BCR-ABL tyrosine kinase.

1 reference

https://api.crossref.org/works/10.1016/S0037-1963(03)70041-9

7 January 2021

BCR-ABL gene mutations in relation to clinical resistance of Philadelphia-chromosome-positive leukaemia to STI571: a prospective study

1 reference

https://api.crossref.org/works/10.1016/S0037-1963(03)70041-9

7 January 2021

Increased neutrophil respiratory burst in bcr-null mutants

1 reference

https://api.crossref.org/works/10.1016/S0037-1963(03)70041-9

7 January 2021

Structural Determinants of Phosphoinositide 3-Kinase Inhibition by Wortmannin, LY294002, Quercetin, Myricetin, and Staurosporine

1 reference

https://api.crossref.org/works/10.1016/S0037-1963(03)70041-9

7 January 2021

Inhibition of heat shock protein HSP90-pp60v-src heteroprotein complex formation by benzoquinone ansamycins: essential role for stress proteins in oncogenic transformation

1 reference

https://api.crossref.org/works/10.1016/S0037-1963(03)70041-9

7 January 2021

Inhibition of bcr-abl oncogene expression by novel deoxyribozymes (DNAzymes).

1 reference

https://api.crossref.org/works/10.1016/S0037-1963(03)70041-9

7 January 2021

Blocking of EGF-dependent cell proliferation by EGF receptor kinase inhibitors

1 reference

https://api.crossref.org/works/10.1016/S0037-1963(03)70041-9

7 January 2021

10.1016/S0037-1963(03)70041-9

Identifiers

DOI

1 reference

6 August 2017

1 reference